ArticleNeoplasia (New York, N.Y.)2008
Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo.
Article in Neoplasia (New York, N.Y.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Proliferation-dependent adipogenic differentiation of progenitor cells in rat coronary artery explants.Stem cell research & therapy · 2026Article
- 5-Bromouracil-gracillin (5BrU-G) complex: an APOBEC3-activated therapeutic strategy exploiting cancer-specific enzymatic activity for selective cytotoxicity.Medical oncology (Northwood, London, England) · 2025Article
- An Overview of the Current State of Cell Viability Assessment Methods Using OECD Classification.International journal of molecular sciences · 2024Review
- Deep learning unlocks label-free viability assessment of cancer spheroids in microfluidics.Lab on a chip · 2024Article
- 5-Bromo-2'-deoxyuridine labeling: historical perspectives, factors influencing the detection, toxicity, and its implications in the neurogenesis.Neural regeneration research · 2024Review
- Pharyngeal pathology in a mouse model of oculopharyngeal muscular dystrophy is associated with impaired basal autophagy in myoblasts.Frontiers in cell and developmental biology · 2022Article
- Review
- Reciprocal Changes in miRNA Expression with Pigmentation and Decreased Proliferation Induced in Mouse B16F1 Melanoma Cells by L-Tyrosine and 5-Bromo-2'-Deoxyuridine.International journal of molecular sciences · 2021Article
- FGF2 modulates simultaneously the mode, the rate of division and the growth fraction in cultures of radial glia.Development (Cambridge, England) · 2020Article
- A balanced evaluation of the evidence for adult neurogenesis in humans: implication for neuropsychiatric disorders.Brain structure & function · 2019Review
- Neurotoxic effects of AZT on developing and adult neurogenesis.Frontiers in neuroscience · 2015Article
- DNA damage signaling, impairment of cell cycle progression, and apoptosis triggered by 5-ethynyl-2'-deoxyuridine incorporated into DNA.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2013Article
- Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Neural stem cells exposed to BrdU lose their global DNA methylation and undergo astrocytic differentiation.Nucleic acids research · 2012Article
- Ethynyldeoxyuridine (EdU) suppresses in vitro population expansion and in vivo tumor progression of human glioblastoma cells.Journal of neuro-oncology · 2011Article
- Alteration of Golgi structure in senescent cells and its regulation by a G protein γ subunit.Cellular signalling · 2011Article
- Dinosaurs and ancient civilizations: reflections on the treatment of cancer.Neoplasia (New York, N.Y.) · 2010Article
- The War on Cancer rages on.Neoplasia (New York, N.Y.) · 2009Article
- Bromodeoxyuridine induces senescence in neural stem and progenitor cells.Stem cells (Dayton, Ohio) · 2008Article
- Neoplasia: the second decade.Neoplasia (New York, N.Y.) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The thymidine analog bromodeoxyuridine (BrdU) is incorporated into newly synthesized DNA and has been shown to increase the susceptibility of incorporating cells to ionizing radiation. However, in the absence of secondary stressors, BrdU is thought to substitute relatively benignly for thymidine and is commonly used to "birth-date" proliferative cells. We report a novel antiproliferative effect of BrdU on cancer cells, which is independent of its role in radiosensitization. A single, brief in vitro exposure to BrdU induces a profound and sustained reduction in the proliferation rate of all cancer cells examined. Cells do not die but variably up-regulate some senescence-associated proteins as they accumulate in the G1 phase of the cell cycle. Bromodeoxyuridine also impairs the proliferative capacity of primary tumor-initiating human glioma cells and may therefore represent a means of targeting cancer stem cells. Finally, conservative in vivo BrdU regimens--in the absence of any other treatment--significantly suppress the progression of gliomas in the highly aggressive, syngeneic RG2 model. These results suggest that BrdU may have an important role as an adjunctive therapeutic for a wide variety of cancers based on new insights into its effect as a negative regulator of cell cycle progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.